image: Insilico Medicine Named a 2025 BostInno Fire Awards Honoree
Credit: Boston Business Journal
The Boston Business Journal’s BostInno Fire Awards 2025, honoring the region’s most innovative and impactful companies, has officially announced its annual honorees. Insilico Medicine, a global clinical-stage biotechnology company powered by generative artificial intelligence (AI), was recognized among Boston’s leading innovators for its pioneering work throughout Biotech.
The awards spotlight the companies and organizations shaping the future of various industries within one of the world’s most dynamic innovation hubs. This year’s list includes visionary leaders across biotechnology, artificial intelligence, cleantech, cybersecurity, robotics and more, who are redefining the boundaries of innovation.
Insilico Medicine earned its place on the 2025 list through a series of groundbreaking achievements demonstrating the real-world impact of generative AI in drug discovery. In June 2025, results from Insilico's lead asset, Rentosertib (ISM001-055), were published in Nature Medicine, with Phase IIa clinical data demonstrating potential signs of lung function restoration measured by improved Forced Vital Capacity (FVC) in idiopathic pulmonary fibrosis (IPF) patients, marking the first clinical proof-of-concept for AI-driven drug development. Insilico has continued to expand its portfolio of AI-generated therapeutics across oncology, cardiometabolic and central nervous system diseases, while also announcing multiple global collaborations that reinforce the scalability of its Pharma.ai platform in accelerating drug discovery and development.
With a growing presence in Boston, Insilico Medicine is contributing to the city’s leadership in biotechnology and artificial intelligence. The recognition emphasizes the company’s continued progress in transforming how new medicines are discovered, designed, and advanced through the clinic.
In 2016, Insilico first described the concept of using generative AI for the design of novel molecules in a peer-reviewed journal, which laid the foundation for the commercially available Pharma.AI platform. Since then, Insilico keeps integrating technical breakthroughs into Pharma.AI platform, which is currently a generative AI-powered solution spanning across biology, chemistry, medicine development and science research. Powered by Pharma.AI, Insilico has nominated 22 developmental/preclinical candidates (DC/PCC) in its comprehensive portfolio of over 30 assets since 2021, received IND clearance for 10 molecules, and completed multiple human clinical trials for two of the most advanced pipelines, with positive results announced.
By integrating the technologies of AI and automation, Insilico has demonstrated significant efficiency boost compared to traditional drug discovery methods (often requiring 2.5-4 years), as announced in the recent key timeline benchmarks for internal DC programs from 2021 to 2024: the average time to DC is 12-18 months, with 60-200 molecules synthesized and tested per program.
About Insilico Medicine
Insilico Medicine, a leading and global AI-driven biotech company, utilizes its proprietary Pharma.AI platform and cutting-stage automated laboratory to accelerate drug discovery and advance innovations in life sciences research. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico is extending the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine.
For more information, please visit www.insilico.com.